Lates News

The Swiss Medicines Agency announced on the 8th that it has approved the Swiss pharmaceutical company Novartis to produce the new-born anti-malaria drug Riamet Baby (also known as Coartem Baby) for marketing. This drug, developed specifically for newborns weighing 2-5 kilograms, fills a crucial gap in the field of malaria treatment, marking an important step forward in the global fight against malaria.